Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Share-based Compensation (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Share-based Compensation for 6 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 25.9% to $13.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.4 million, a 33.69% decrease, with the full-year FY2025 number at $62.4 million, down 33.69% from a year prior.
  • Share-based Compensation was $13.1 million for Q4 2025 at Relay Therapeutics, down from $15.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $27.2 million in Q1 2024 to a low of $9.7 million in Q1 2021.
  • A 5-year average of $17.4 million and a median of $15.8 million in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 564.67% in 2021, then tumbled 45.96% in 2025.
  • Relay Therapeutics' Share-based Compensation stood at $10.2 million in 2021, then soared by 35.22% to $13.8 million in 2022, then surged by 39.44% to $19.3 million in 2023, then fell by 8.47% to $17.6 million in 2024, then dropped by 25.9% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Share-based Compensation are $13.1 million (Q4 2025), $15.5 million (Q3 2025), and $14.5 million (Q2 2025).